Frankfurt - Delayed Quote EUR

Braxia Scientific Corp. (4960.F)

0.0050 0.0000 (0.00%)
At close: May 17 at 8:14 AM GMT+2
Loading Chart for 4960.F
DELL
  • Previous Close 0.0050
  • Open 0.0050
  • Bid 0.0010 x --
  • Ask 0.0060 x --
  • Day's Range 0.0050 - 0.0050
  • 52 Week Range 0.0015 - 0.0200
  • Volume 43,465
  • Avg. Volume 17,320
  • Market Cap (intraday) 1.416M
  • Beta (5Y Monthly) 1.28
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date Jul 22, 2024 - Jul 26, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. The company is headquartered in Toronto, Ontario.

braxiascientific.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 4960.F

Performance Overview: 4960.F

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

4960.F
52.38%
S&P/TSX Composite index
7.19%

1-Year Return

4960.F
64.29%
S&P/TSX Composite index
10.98%

3-Year Return

4960.F
98.00%
S&P/TSX Composite index
16.00%

5-Year Return

4960.F
97.54%
S&P/TSX Composite index
50.19%

Compare To: 4960.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4960.F

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    957.23k

  • Enterprise Value

    1.30M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.87

  • Price/Book (mrq)

    3.60

  • Enterprise Value/Revenue

    0.87

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.36%

  • Return on Equity (ttm)

    -254.59%

  • Revenue (ttm)

    2.21M

  • Net Income Avi to Common (ttm)

    -9.64M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    128.34k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -970.83k

Research Analysis: 4960.F

Company Insights: 4960.F

Research Reports: 4960.F